Clinical Scorecard: Efficacy and Safety of Tebentafusp in Patients with Metastatic Uveal Melanoma: A Comprehensive Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Tebentafusp activates T cells by targeting the gp100 antigen via a high-affinity T-cell receptor and engaging CD3, enhancing T-cell activation and anti-tumor response.
Target Population
Care Setting
Key Highlights
Median overall survival (OS) of 21.3 months and progression-free survival (PFS) of 3.6 months, indicating a modest survival benefit.
Overall response rate (ORR) of 9% and disease control rate (DCR) of 27%, highlighting the need for careful patient selection.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Monitor for cytokine release syndrome and treatment-related adverse events during tebentafusp therapy, with specific attention to the first few weeks post-initiation.
Risks
Patient & Prescribing Data
631 patients with evaluable metastatic uveal melanoma.
